Chemotherapy-induced peripheral neuropathy (CIPN) is one of the common complications of cancer treatment and involves paresthesia, numbness and/or burning pain in distal limbs. This condition has a high health impact because it is associated with psychological distress, fall risk, and poor sleep quality. Furthermore, it impairs patients' daily activities and thereby decreases their quality of life. The overall incidence of CIPN is approximately 68% in the first month after chemotherapy. The available evidence for preventive and therapeutic options for CIPN is limited. Therefore, only symptom management based on pharmacological and/or physical therapy is applied with limited success. Photobiomodulation (PBM) has the potential to reduce the development of CIPN in breast cancer patients. PBM uses visible and/or (near)-infrared light at a low power produced by laser diodes or light-emitting diodes (LED) to stimulate tissue repair and reduce inflammation and (neuropathic) pain. Additionally, research demonstrated that the use of PBM for three weeks in a curative setting reduces the CIPN symptoms, which is associated with a better QoL. According to the updated WALT 2022 recommendations it is most optimal for neuropathy patients to receive twelve PBM sessions. The aim of this project is to evaluate the role of PBM administered to patients with " de novo " early signs of Peripheral neuropathy (PN) that are supposed to be related to ongoing anti-cancer therapy.
All the patients admitted for medical oncological therapy to the day care facility (Hôpital de Jour) are eligible for the protocol.
Age 18 years or above
Have no documented or observable psychiatric or neurological disorders that might interfere with study participation (e.g., dementia or psychosis)
Be able to understand the ICF and study-related questionnaires
severe or unstable cardio-respiratory or musculoskeletal disease
Peripheral neuropathy previous to chemotherapy
Receiving potentially neurotoxic therapies other than given for cancer treatment
Interruption of more than two consecutive laser treatments
Crossover
Photobiomodulation
DevicePatients will receive 20 Joule/cm2
severity of CIPN measured by modified Total Neurpathy Score m-TNS
Include several simple neurological tests
Pain & satisfaction by Numeric Rating Scale (0-10)
Pain \& satisfaction by Numeric Rating Scale (0-10)
Mobility by 6min walking test
Mobility by 6min walking test and
Quality of life by FACT-GOG-NTX questionnair
Quality of life by FACT-GOG-NTX questionnaire
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
